Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Depreciation & Amortization (CF): 2021-2025

Historic Depreciation & Amortization (CF) for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to $1.9 million.

  • Prime Medicine's Depreciation & Amortization (CF) rose 20.73% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 26.58%. This contributed to the annual value of $6.1 million for FY2024, which is 31.70% up from last year.
  • As of Q3 2025, Prime Medicine's Depreciation & Amortization (CF) stood at $1.9 million, which was up 0.91% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Depreciation & Amortization (CF) peaked at $1.9 million during Q3 2025, and registered a low of $200,000 during Q3 2021.
  • Over the past 3 years, Prime Medicine's median Depreciation & Amortization (CF) value was $1.5 million (recorded in 2024), while the average stood at $1.5 million.
  • Data for Prime Medicine's Depreciation & Amortization (CF) shows a peak YoY skyrocketed of 259.04% (in 2023) over the last 5 years.
  • Prime Medicine's Depreciation & Amortization (CF) (Quarterly) stood at $261,000 in 2021, then skyrocketed by 233.33% to $870,000 in 2022, then surged by 43.33% to $1.2 million in 2023, then skyrocketed by 37.69% to $1.7 million in 2024, then grew by 20.73% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.9 million for Q2 2025, and $1.7 million during Q1 2025.